C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases TUCSON, Ariz., Sept. 1, 2022 — Critical Path Institute (C-Path) today announced the launch of a pre-consortium collaboration foc
Four PKD Reports Published in CJASN C-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit h
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platfo
Oak Hill Bio Joins C-Path’s International Neonatal Consortium TUCSON, Ariz., Aug. 24, 2022 — Critical Path Institute (C-Path) today announced that Oak Hill Bio (Oak Hill), a clinical-stage n
August 23, 2022 Obtaining and Using TPOXX Tecovirimat for Treatment of Monkeypox An overview of how to obtain and use Tecovirimat (TPOXX) during the 2022 monkeypox public health emergency under Expanded Access I